Ultrasound Targeted Molecular Imaging in Large Arteries to Predict AAA Risk

大动脉超声靶向分子成像可预测 AAA 风险

基本信息

  • 批准号:
    9194510
  • 负责人:
  • 金额:
    $ 40.57万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-21 至 2020-04-30
  • 项目状态:
    已结题

项目摘要

Abdominal aortic aneurysm (AAA) causes over 10,000 deaths annually in the US. The majority of AAA are silent and asymptomatic until rupture. If detected early, surgical interventions have been proven effective with in-hospital mortalities < 4% compared to mortality higher than 40% in already ruptured AAAs. Ultrasound- based maximum diameter measurements of AAA is currently the primary determinant of its rupture risk with 5.5 cm often used as the decision criteria. However, it has been reported that up to 23% of AAAs ruptured at a diameter less than 5 cm and up to 60% of AAAs with a diameter greater than 5 cm never experienced rupture Thus, more reliable predictors of rupture risk are urgently needed. In particular, a molecular imaging positive finding may assist with risk stratification in cases where anatomic-based findings are ambiguous (e.g. aortic diameter in range 4.5 - 6.5 cm). Molecular imaging is a promising approach for early detection of AAA risk that contrasts with anatomical imaging in which only relatively late AAA progression is detectable. The correlation between risk of AAA rupture and biomarkers has been demonstrated. MRI, optical, and PET methods have all demonstrated pre-clinical success in detection of markers for AAA rupture but none of these modalities simultaneously meets the need for rapid, low-cost, radiation-free, molecular marker detection necessary to achieve widespread clinical adoption. Ultrasound-based molecular imaging is an ideal modality because it meets the above needs and existing instrumentation, already in use for making diameter measurements during existing AAA screening protocols, requires only very minor adaptation. Unfortunately, existing ultrasound- based molecular imaging is unable to measure molecular marker concentration in large blood vessel environments, and thus AAA risk assessment using ultrasound has not yet been attempted. The present investigators have recently invented a new ultrasound-based molecular imaging strategy that overcomes the limitations of previous techniques in large blood vessel environments. This method, referred to as “modulated Acoustic Radiation Force” (mARF)-based imaging, is the first ultrasound technology to demonstrate quantitative measurements of molecular marker con-centration (in units of sites/μm2) in large blood vessels. Earlier and more accurate prediction of future AAA rupture risk will improve mortality rates and reduce healthcare costs associated with AAA.
在美国,腹主动脉瘤(AAA)每年导致超过1万人死亡。大多数AAA级游戏都是如此

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John A Hossack其他文献

John A Hossack的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John A Hossack', 18)}}的其他基金

Accelerated Low Dose Thrombolytic Catheter Directed Sonothrombolysis
加速低剂量溶栓导管定向声溶栓
  • 批准号:
    10192806
  • 财政年份:
    2018
  • 资助金额:
    $ 40.57万
  • 项目类别:
Tailoring ultrasound technology to explore mechanisms of activation of the splenic neuroimmune axis in attenuating acute organ injury.
定制超声技术探索脾神经免疫轴激活减轻急性器官损伤的机制。
  • 批准号:
    9341636
  • 财政年份:
    2016
  • 资助金额:
    $ 40.57万
  • 项目类别:
Tailoring ultrasound technology to explore mechanisms of activation of the splenic neuroimmune axis in attenuating acute organ injury.
定制超声技术探索脾神经免疫轴激活减轻急性器官损伤的机制。
  • 批准号:
    9150562
  • 财政年份:
    2015
  • 资助金额:
    $ 40.57万
  • 项目类别:
Tailoring ultrasound technology to explore mechanisms of activation of the splenic neuroimmune axis in attenuating acute organ injury.
定制超声技术探索脾神经免疫轴激活减轻急性器官损伤的机制。
  • 批准号:
    9054531
  • 财政年份:
    2015
  • 资助金额:
    $ 40.57万
  • 项目类别:
Ultrasound Targeted Molecular Imaging in Large Arteries to Diagnose Stroke Risk
大动脉超声靶向分子成像诊断中风风险
  • 批准号:
    8528708
  • 财政年份:
    2012
  • 资助金额:
    $ 40.57万
  • 项目类别:
Ultrasound Targeted Molecular Imaging in Large Arteries to Diagnose Stroke Risk
大动脉超声靶向分子成像诊断中风风险
  • 批准号:
    8371330
  • 财政年份:
    2012
  • 资助金额:
    $ 40.57万
  • 项目类别:
Ultrasound Targeted Molecular Imaging in Large Arteries to Diagnose Stroke Risk
大动脉超声靶向分子成像诊断中风风险
  • 批准号:
    8675928
  • 财政年份:
    2012
  • 资助金额:
    $ 40.57万
  • 项目类别:
PiV Ultra 12 - 24 Ultra High Speed Camera for Ultrasound Microbubble Research
PiV Ultra 12 - 24 用于超声微泡研究的超高速相机
  • 批准号:
    7595606
  • 财政年份:
    2009
  • 资助金额:
    $ 40.57万
  • 项目类别:
VisualSonics Vevo 2100 Small Animal Ultrasound Imaging System and Accessories
VisualSonics Vevo 2100 小动物超声成像系统和配件
  • 批准号:
    7792714
  • 财政年份:
    2009
  • 资助金额:
    $ 40.57万
  • 项目类别:
Molecular Targeted, Focused, Ultrasound-Based Delivery of Antiproliferative Drugs
抗增殖药物的分子靶向、聚焦、超声递送
  • 批准号:
    8296580
  • 财政年份:
    2008
  • 资助金额:
    $ 40.57万
  • 项目类别:

相似海外基金

Establishment of human abdominal aortic aneurysm wall strength prediction model using Ex Vivo Superparamagnetic Iron Oxide&#8211;Enhanced Magnetic Resonance Imaging
利用Ex Vivo超顺磁性氧化铁建立人体腹主动脉瘤壁强度预测模型
  • 批准号:
    23K08226
  • 财政年份:
    2023
  • 资助金额:
    $ 40.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Vascular smooth muscle cell ferroptosis and abdominal aortic aneurysm
血管平滑肌细胞铁死亡与腹主动脉瘤
  • 批准号:
    10733477
  • 财政年份:
    2023
  • 资助金额:
    $ 40.57万
  • 项目类别:
Extracellular Vesicle Delivery System for Treatment of Abdominal Aortic Aneurysm
细胞外囊泡递送系统治疗腹主动脉瘤
  • 批准号:
    10751123
  • 财政年份:
    2023
  • 资助金额:
    $ 40.57万
  • 项目类别:
I-Corps: A Clinical Decision Support Tool to Manage Abdominal Aortic Aneurysm Patients
I-Corps:管理腹主动脉瘤患者的临床决策支持工具
  • 批准号:
    2318665
  • 财政年份:
    2023
  • 资助金额:
    $ 40.57万
  • 项目类别:
    Standard Grant
Atherosclerosis drives arterial damage and abdominal aortic aneurysm formation and rupture
动脉粥样硬化导致动脉损伤和腹主动脉瘤形成和破裂
  • 批准号:
    483212
  • 财政年份:
    2023
  • 资助金额:
    $ 40.57万
  • 项目类别:
    Operating Grants
Development of phospholipid-based nanotherapeutics for treating abdominal aortic aneurysm
开发基于磷脂的纳米疗法治疗腹主动脉瘤
  • 批准号:
    10749980
  • 财政年份:
    2023
  • 资助金额:
    $ 40.57万
  • 项目类别:
Impact of PCSK9 inhibition on abdominal aortic aneurysm pathobiology and growth
PCSK9 抑制对腹主动脉瘤病理学和生长的影响
  • 批准号:
    10566800
  • 财政年份:
    2023
  • 资助金额:
    $ 40.57万
  • 项目类别:
The Role of Amino Acid Starvation Response Kinase GCN2 in Abdominal Aortic Aneurysm
氨基酸饥饿反应激酶 GCN2 在腹主动脉瘤中的作用
  • 批准号:
    10584543
  • 财政年份:
    2022
  • 资助金额:
    $ 40.57万
  • 项目类别:
Atherosclerotic process drives arterial damage, abdominal aortic aneurysm formation, and rupture
动脉粥样硬化过程导致动脉损伤、腹主动脉瘤形成和破裂
  • 批准号:
    477264
  • 财政年份:
    2022
  • 资助金额:
    $ 40.57万
  • 项目类别:
    Operating Grants
Endovascular Orifice Detection (EOrD) Device for in situ Fenestration of Abdominal Aortic Aneurysm
用于腹主动脉瘤原位开窗的血管内孔口检测 (EOrD) 装置
  • 批准号:
    10453104
  • 财政年份:
    2022
  • 资助金额:
    $ 40.57万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了